Compare JPMorgan Chase & Co (JPM) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Tenet Healthcare Corporation — how do they compare? JPMorgan Chase & Co trades at $345.3 (market cap $900.78B), while Tenet Healthcare Corporation trades at $196.03 (market cap $16.74B). The key difference: JPMorgan Chase & Co is far larger — about 53.8× Tenet Healthcare Corporation's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| JPM | THC | |
|---|---|---|
Market Cap | $900.78B | $16.74B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $244.80 |
52-Week Low | $282.84 | $148.38 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $26.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $345.23, up 1.21% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside a consensus price target of $372.73, signal positive momentum. Revenue growth is robust, rising to $181.85B in 2025, though net income dipped slightly to $57.05B. The stock benefits from institutional accumulation and media focus on CEO Jamie Dimon's economic insights.
The outlook for JPM remains favorable, driven by earnings resilience and sector leadership, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. With a moderate buy rating from analysts and a reasonable P/E of 14.52, the stock offers value, though investors should weigh macroeconomic headwinds against its solid fundamentals.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten EPS estimates for three consecutive quarters, with a Q2 2026 report due July 24. Valuation metrics appear attractive with a P/E of 10.11 and P/S of 0.79. Revenue and net income are projected to grow in 2026, supported by expansion in outpatient care.
The outlook is positive given analyst consensus with 81% buy ratings and a $234.63 price target, implying 21% upside. Risks include potential pressure from lower patient days and high debt levels. Earnings growth and ambulatory care performance remain key catalysts for near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
